Lessons from routine dose adjustment of tacrolimus in renal transplant patients based on global exposure

Therapeutic Drug Monitoring

Volumn 35, Issue 3, 2013, Pages 322-327

  Saint Marcoux, Franck ^a,b   Woillard, Jean Baptiste ^a,b   Jurado, Camille ^a   Marquet, Pierre ^a,b  

^a LIMOGES UNIVERSITY HOSPITAL   (France)

^b UNIVERSITY OF LIMOGES   (France)

Author keywords

Areaunder the curve; Bayesian estimation; Tacrolimus; Therapeutic drug monitoring; Transplantation

Indexed keywords

MYCOPHENOLIC ACID; TACROLIMUS;

ADULT; AREA UNDER THE CURVE; ARTICLE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EXPOSURE; DRUG MONITORING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; PHARMACOKINETICS; PLASMA CONCENTRATION-TIME CURVE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RECIPIENT; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; AREA UNDER CURVE; BAYES THEOREM; DATABASES, FACTUAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MIDDLE AGED; MODELS, BIOLOGICAL; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; TACROLIMUS; TIME FACTORS; YOUNG ADULT;

EID: 84880081142     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e318285e779     Document Type: Article

References (21)

1. Cross SA, Perry CM. Tacrolimus once-daily formulation: in the prophylaxis of transplant rejection in renal or liver allograft recipients. Drugs. 2007;67:1931-1943. (Pubitemid 47347405)
2. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet. 2004;43: 623-653. (Pubitemid 38981845)
3. Wallemacq P, Armstrong VW, Brunet M, et al. Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference. Ther Drug Monit. 2009;31:139-152.
4. Scholten EM, Cremers SC, Schoemaker RC, et al. AUC-guided dosing of tacrolimus prevents progressive systemic overexposure in renal transplant recipients. Kidney Int. 2005;67:2440-2447. (Pubitemid 41623408)
5. Benkali K, Premaud A, Picard N, et al. Tacrolimus population pharmacokinetic-pharmacogenetic analysis and Bayesian estimation in renal transplant recipients. Clin Pharmacokinet. 2009;48:805-816.
6. Saint-Marcoux F, Debord J, Undre N, et al. Pharmacokinetic modeling and development of Bayesian estimators in kidney transplant patients receiving the tacrolimus once-daily formulation. Ther Drug Monit. 2010;32:129-135.
7. Saint-Marcoux F, Debord J, Parant F, et al. Development and evaluation of a simulation procedure to take into account various assays for the Bayesian dose adjustment of tacrolimus. Ther Drug Monit. 2011;33: 171-177.
8. Woillard JB, de Winter BC, Kamar N, et al. Population pharmacokinetic model and Bayesian estimator for two tacrolimus formulations-twice daily Prograf and once daily Advagraf. Br J Clin Pharmacol. 2011;71: 391-402.
9. European Medicines Agency. Advagraf: summary of product characteristics. Available at: http://www.emea.europea.eu. Accessed June, 2012.
10. Saint-Marcoux F, Vandierdonck S, Prémaud A, et al. Large scale analysis of routine dose adjustments of mycophenolate mofetil based on global exposure in renal transplant patients. Ther Drug Monit. 2011;33:285-294.
11. Bonate PL. The art of modelling. In: Pharmacokinetic-Pharmacodynamic Modeling and Simulation. Lightning Source UK Ltd. Milton Keynes, United Kingdom: Elsevier Editions; 2006.
12. Schiff J, Cole E, Cantarovich M. Therapeutic monitoring of calcineurin inhibitors for the nephrologists. Clin J Am Soc Nephrol. 2007;2:374-384.
13. Pinheiro JC, Bates DM. Mixed Effects Models in S and S-Plus. New-York, NY: Springer-Verlag Editions; 2009.
14. Jørgensen KA, Povlsen JV, Madsen S, et al. Two-hour blood tacrolimus levels are not superior to trough levels as estimates of the area under the curve in tacrolimus-treated renal transplant patients. Transplant Proc. 2002;34:1721-1722.
15. Kimikawa M, Kamoya K, Toma H, et al. Effective oral administration of tacrolimus in renal transplant recipients. Clin Transplant. 2001;15:324-329. (Pubitemid 32936879)
16. Undre NA, van Hooff J, Christiaans M, et al. Low systemic exposure to tacrolimus correlates with acute rejection. Transplant Proc. 1999;31: 296-298.
17. Uchida K, Tominaga Y, Haba T, et al. Usefulness of monitoring of AUC(0-4h) during the induction period of immunosuppressive therapy with tacrolimus after renal transplantation. Transplant Proc. 2002;34: 1736-1737.
18. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007;357: 2562-2575. (Pubitemid 350294223)
19. Ekberg H, Mamelok RD, Pearson TC, et al. The challenge of achieving target drug concentrations in clinical trials: experience from the Symphony study. Transplantation. 2009;87:1360-1366.
20. Undre NA, Schafer A. Factors affecting the pharmacokinetics of tacrolimus in the first year after renal transplantation. European Tacrolimus Multicentre Renal Study Group. Transplant Proc. 1998;30:1261-1263. (Pubitemid 28309564)
21. Pou L, Brunet M, Andres I, et al. Influence of posttransplant time on dose and concentration of tacrolimus in liver transplant patients. Transpl Int. 1998;11 (suppl 1):S270-S271. (Pubitemid 128683557)